An Introduction to Survival Statistics: Kaplan-Meier Analysis
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Studies of how patients re¬spond to treatment over time are fundamentally impor¬tant to understanding how therapies influence quality of life and progression of disease during survivorship.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Baselga, J., Cortés, J., Kim, S.-B., Im, S.-A., Hegg, R., Im, Y.-H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113216 · Cited by 2,532 · cited 8×
“That is, in Baselga et al. (2012), the PFS K-M plot indicates all points at which events took place as tick marks on the plot (Figure 3).”
BackgroundMethodInfluentialPeto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1976) · British Journal of Cancer · doi:10.1038/bjc.1976.220 · Cited by 2,294
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Swain, S. M., Baselga, J., Kim, S.-B., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Heeson, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1413513 · Cited by 2,164 · cited 6×
“Estimates of OS shown in Table 3 illustrate the fact that the likelihood of being alive was greater at 1, 2, 3, and 4 years for patients receiving pertuzumab than those in the control group (Swain et al., 2015).”
BackgroundMethodInfluentialSwain, S. M., Kim, S.-B., Cortés, J., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Knott, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70130-x · Cited by 1,006 · cited 3×
“DUDLEY, WICKHAM, and COOMBS ings were published in three articles (Baselga et al., 2012; Swain et al., 2013, 2015).”
BackgroundA practical guide to understanding Kaplan‐Meier curves
Rich, J. T., Neely, J. G., Paniello, R. C., Voelker, C. C. J., Nussenbaum, B., & Wang, E. W. (2010) · Otolaryngology–Head and Neck Surgery · doi:10.1016/j.otohns.2010.05.007 · Cited by 962 · cited 15×
“, 2012), and are similarly calculated by summing χ2 for each event, providing the final observed and expected numbers for the full K-M curve (Rich et al., 2010).”
BackgroundMethodInfluentialHazard Ratio in Clinical Trials
Spruance, S. L., Reid, J. E., Grace, M., & Samore, M. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.8.2787-2792.2004 · Cited by 547 · cited 1×
“A hazard ratio of greater than 1 or less than 1 means that survival was better in one of the groups (Spruance, Reid, Grace, & Samore, 2004).”
BackgroundSurvival plots of time-to-event outcomes in clinical trials: good practice and pitfalls
Pocock, S. J., Clayton, T. C., & Altman, D. G. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08594-x · Cited by 513 · cited 3×
“The reported CIs overlapped only at year 1, meaning that these values were within the bounds of random chance (Pocock et al., 2002).”
BackgroundMedicine Residents' Understanding of the Biostatistics and Results in the Medical Literature
Windish, D. M., Huot, S. J., & Green, M. L. (2007) · JAMA · doi:10.1001/jama.298.9.1010 · Cited by 423 · cited 1×
“No published research that addressed oncology APs’ knowledge and ability to interpret statistical tests was found, but a study of medical residents examined their knowledge within the context of statistical procedures used in medical studies (Windish, Huot, & Green, 2007).”
BackgroundThe analysis of survival data: the Kaplan–Meier method
Jager, K. J., van Dijk, P. C., Zoccali, C., & Dekker, F. W. (2008) · Kidney International · doi:10.1038/ki.2008.217 · Cited by 259 · cited 6×
“The log-rank test calculates chi-squares ( χ 2 ) for each event time, which are summed to calculate an ultimate chi-square for each arm (Jager et al., 2008; Rich et al., 2010).”
BackgroundMethodInfluentialWhen You Look Matters: The Effect of Assessment Schedule on Progression-Free Survival
Panageas, K. S., Ben-Porat, L., Dickler, M. N., Chapman, P. B., & Schrag, D. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk091 · Cited by 182 · cited 1×
“PFS is frequently the primary endpoint, particularly as new targeted therapies become available (Panageas et al., 2007).”
BackgroundProblems in dealing with missing data and informative censoring in clinical trials
Shih, W. J. (2002) · Current Controlled Trials in Cardiovascular Medicine · doi:10.1186/1468-6708-3-4 · Cited by 170
When (Not) to Stop a Clinical Trial for Benefit
Pocock, S. J. (2005) · JAMA · doi:10.1001/jama.294.17.2228 · Cited by 163 · cited 1×
“A predetermined stopping boundary is a method to determine if a study can be stopped early—for instance, when the primary outcome variable has been reached (Pocock, 2005).”
MethodHazard ratios in cancer clinical trials—a primer
Blagoev, K. B., Wilkerson, J., & Fojo, T. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.217 · Cited by 66 · cited 4×
“Hazard ratios quantify the opposite likelihood: that the “hazardous” event will occur during study intervals (Blagoev et al., 2012), and are similarly calculated by summing χ 2 for each event, providing the final observed and expected numbers for the full K-M curve (Rich et al., 2010).”
BackgroundInfluentialBenefits and limitations of Kaplan?Meier calculations of survival chance in cancer surgery
Bollschweiler, E. (2003) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-003-0410-6 · Cited by 56 · cited 1×
“…to halt estimations of survival curves when the proportion of patients who have not experienced the event becomes unduly small, perhaps when only 10% to 20% of an original large sample or fewer than 10 patients in a small study are still being followed (Bollschweiler, 2003; Pocock et al., 2002).”
BackgroundSymptom Trajectories in Posttreatment Cancer Survivors
Brant, J. M., Beck, S., Dudley, W. N., Cobb, P., Pepper, G., & Miaskowski, C. (2011) · Cancer Nursing · doi:10.1097/ncc.0b013e3181f04ae9 · Cited by 48 · cited 2×
“…over time in continuous variables (e.g., patient self-reports of pain, fatigue, or nausea) in the same individuals, repeated measures are typically analyzed using analysis of variance (ANOVA) or perhaps latent growth curve modeling (Brant et al., 2011; Dudley, McGuire, Peterson, & Wong, 2009).”
MethodWhen to Stop a Clinical Trial Early for Benefit: Lessons Learned and Future Approaches
Zannad, F. M., Stough, W. G., McMurray, J. J. V., Remme, W. J., Pitt, B., BORER, J. S., Geller, N. L., & Pocock, S. (2012) · Circulation Heart Failure · doi:10.1161/circheartfailure.111.965707 · Cited by 28 · cited 2×
“This is crucial to legitimately support clinically relevant, evidence-based practice; to achieve an adequate sample size within the intended duration of a trial; to positively change particular therapies; to meet the goals of researchers and regulators to conduct scientifically rigorous studies; and to disseminate dat…”
BackgroundMount, D. W., Putnam, C. W., Centouri, S. M., Manziello, A., Pandey, R., Garland, L. L., & Martinez, J. D. (2014) · BMC Medical Genomics · doi:10.1186/1755-8794-7-33 · Cited by 21
Cautionary Note Regarding the Use of CIs Obtained From Kaplan-Meier Survival Curves
Carter, R. E., & Huang, P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.8011 · Cited by 15
Cited by
Deep learning in ovarian cancer diagnosis: a comprehensive review of various imaging modalities
Sadeghi, M. H., Sina, S., Omidi, H., Farshchitabrizi, A. H., & Alavi, M. (2024) · Polish Journal of Radiology · doi:10.5114/pjr.2024.134817 · Cited by 54
“Kaplan-Meier [79] analysis and Cox proportional hazards model confirmed the model’s ability to distinguish patients with positive therapeutic effects from those with disease progression after treatment [80].”
MethodYang, L., McClean, S., Donnelly, M., Khan, K., & Burke, K. (2024) · ACM Transactions on Knowledge Discovery from Data · doi:10.1145/3669942 · Cited by 9
“The KM curves [15] are used to describe data distributions in a non-parametric way.”
Metadata
- Authors
- N. Dudley, P., Wickham, P., & Coombs, M.
- Venue
- Journal of the Advanced Practitioner in Oncology
- Publisher
- Harborside Press, LLC
- Published
- 2016-02-01
- Volume
- 7
- Issue
- 1
- Pages
- 91-100
- ISSN
- 2150-0878 (ISSN-L)
- OpenAlex
- W2530581966
- Cited by
- 168
- References
- 20
- FWCI
- 6.82
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.